Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC

Date

19 Dec 2015

Session

Thoracic cancers

Presenters

Tony Mok

Citation

Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532

Authors

T. Mok1, N. Saijo2, S. Thongprasert3, J.C. Yang4, Y. Wu5, H. Young6, V. Haddad7, M. Fukuoka8, H. Jiang9

Author affiliations

  • 1 Department Of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, . - Sha Tin/HK
  • 2 Division Of Medical Oncology, Kinki University School of Medicine, Osakasayama/JP
  • 3 Department Of Medicine, Maharaj Nakorn Chiang Mai Hospital, Chiangmai/TH
  • 4 National Taiwan University, National Taiwan University Hospital and College of Medicine, 10048 - Taipei/TW
  • 5 Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 510080 - Guangzhou/CN
  • 6 Global Medicines Development, AstraZeneca, Cambridge/GB
  • 7 Biostatistics And Information Sciences, AstraZeneca, Royston/GB
  • 8 Fourth Dept Of Internal Medicine, Kinki University School of Medicine, Osakasayama/JP
  • 9 Global R & D, AstraZeneca, Shanghai/CN
More

Abstract 1092

Aim/Background

In IPASS (NCT00322452), 1217 Asian pts were randomised to 1st-line G (n = 609) or C/P (n = 608). Investigator-assessed progression-free survival (PFS; primary endpoint) significantly favoured G and C/P in the EGFR mutation-positive and -negative subgroups, respectively (Table). Objective response rate (ORR) followed a similar trend; median duration of response (DoR) with G was 8.7 months in pts with EGFR mutation-positive tumours (Table). Post hoc analyses of PFS, ORR and DoR according to BICR were requested by the FDA.

Methods

CT scans from pts with EGFR mutation-positive NSCLC were retrospectively collected post-study and reviewed by a third party (double read with adjudication paradigm with predefined assessment criteria for RECIST progression) independently of AstraZeneca. Reviewers were blinded to investigational site scan results and treatment assignment.

Results

Scans from 186 pts with EGFR mutation-positive tumours were available for BICR (154 [82.8%] female, 178 [95.7%] never smokers, 175 [94.1%] WHO PS 0/1; consistent with the 261 EGFR mutation-positive population). According to BICR, at data cut-off (14 April 2008), 55 (62.5%) and 69 (70.4%) progression events had occurred in the G and C/P arms, respectively. Consistent with investigator assessment, PFS according to BICR significantly favoured G in the EGFR mutation-positive subgroup (n = 186; HR 0.544; 95% CI 0.375–0.786, p = 0.0012; median PFS 10.9 vs 7.4 months). Overall, BICR ORR and median DoR data were also consistent with investigator assessment (Table).

Overall IPASS

EGFR mutation-positive (n = 261) EGFR mutation-negative (n = 176)
PFS, HR (95% CI) 0.48 (0.36-0.64) p < 0.001 2.85 (2.05-3.98) p < 0.001
Median PFS G vs C/P, months 9.5 vs 6.3 1.5 vs 5.5
ORR, OR (95% CI) 2.75 (1.65-4.60) p = 0.0001 0.04 (0.01-0.27) p = 0.0013
EGFR mutation-positive population
Overall IPASS IPASS BICR
G (n = 132) C/P (n = 129) G (n = 88) C/P (n = 98)
ORR, % (95% CI) 71.2 (N/A) 47.3 (N/A) 67.1 (56.2-76.7) 40.8 (31.0-51.2)
Responders, n (%) 94 (71.2) 61 (47.3) 59 (67.0) 40 (40.8)
Non-responders, n (%) 38 (28.8) 68 (52.7) 29 (33.0) 58 (59.2)
Median DoR, months (95% CI)a 8.7 (N/A) N/A 9.6 (7.4-12.5) 5.5 (4.1-5.7)

HR, hazard ratio; N/A, not available; OR, odds ratio.

aPts with EGFR mutation-positive tumours who responded to G.

Conclusions

A subset of pts from the IPASS EGFR mutation-positive subgroup showed significant improvement in PFS, ORR and DoR with 1st-line G vs C/P when analysed by BICR, consistent with investigator assessment.

Clinical trial identification

NCT00322452

Disclosure

T. Mok: honoraria: AstraZeneca (AZ), Roche (Ro), Eli Lilly (EL), Merck Serono (MS), Eisai, BMS, AVEO, Pfizer (Pf), Taiho, Boehringer Ingelheim (BI), Novartis, GSK, Clovis, Amgen (Am), Janssen, BioMarin; speaker: AZ, Ro, EL, BI, MS, Pf, Am; research funding: AZ. N. Saijo: grant support from: AstraZeneca, Chugai, Takeda, Taiho; owns equity in Takeda. S. Thongprasert: consultant fees from: AstraZeneca, Pfizer, Sanofi-Aventis; lecture fees from: AstraZeneca, Eli Lilly, Sanofi-Aventis; grant support from: AstraZeneca, Sanofi-Aventis, Pfizer. J.C.-H. Yang: honoraria: AstraZeneca (AZ), Boehringer Ingelheim (BI), Eli Lilly (EL), Pfizer (Pf), Roche (Ro); consultant: Astellas, AZ, Bayer, BI, Celgene, Clovis, Daiichi-Sankyo, EL, Merck, MSD, Novartis, Pf, Ro/Genentech; research funding: BI. Y.-L. Wu: speaker fees from: AstraZeneca, Roche, Eli Lilly, Pfizer, Sanofi. H. Young, V. Haddad, H. Jiang: employee of AstraZeneca and holds shares in AstraZeneca. M. Fukuoka: advisor for honoraria from: Asterus, Eisai, Chugai, Kyowa Hakko Kirin, Dainippon-Sumitomo, AstraZeneca.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings